Form 4/A for URGN UroGen Pharma Ltd.
Accepted 2024-02-05 00:00:00 ET · period of report 2024-01-31 · accession 0001437749-24-003155 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MA | 2024-02-05 | 2024-02-01 | URGN | Smith Jason Drew | GC | S - Sale | $15.78 | -4,993 | 20.1K | -20% | -$78.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-02-01 | S | D | 417 | $15.78 | 18,824 | D | — | — | (F1) This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024. (F2) This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024. |
| 2 | Common | Ordinary Shares | 2024-02-01 | S | D | 3,328 | $15.78 | 23,414 | D | — | — | (F1) This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024. (F2) This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024. |
| 3 | Common | Ordinary Shares | 2024-02-01 | S | D | 1,248 | $15.78 | 20,076 | D | — | — | (F1) This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024. (F2) This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024. |